HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical translation in multiple myeloma: from bench to bedside.

Abstract
The outlook for patients with multiple myeloma (MM) has improved significantly with the development of new and more effective therapies, particularly the immunomodulatory agents and proteasome inhibitors. Preclinical and correlative science investigations have played a critical role in these advances, providing important insights regarding mechanisms of neoplasia, inhibition of tumor growth, and drug resistance. This review highlights the evolution of drug development in MM, the manner in which preclinical models have contributed to the process of drug discovery, and important insights gained during the current era of MM drug development.
AuthorsJacob Laubach, Teru Hideshima, Paul Richardson, Kenneth Anderson
JournalSeminars in oncology (Semin Oncol) Vol. 40 Issue 5 Pg. 549-53 (Oct 2013) ISSN: 1532-8708 [Electronic] United States
PMID24135399 (Publication Type: Journal Article, Review)
Copyright© 2013 Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Boronic Acids
  • Proteasome Inhibitors
  • Pyrazines
  • Bortezomib
  • Proteasome Endopeptidase Complex
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Boronic Acids (therapeutic use)
  • Bortezomib
  • Drug Design
  • Humans
  • Mice
  • Multiple Myeloma (drug therapy, physiopathology)
  • Proteasome Endopeptidase Complex
  • Proteasome Inhibitors (therapeutic use)
  • Pyrazines (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: